A functional screen identifies specific micrornas capable of inhibiting human melanoma cell viability

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Poell, Jos B ^a   van Haastert, Rick J ^b   de Gunst, Thijs ^b   Schultz, Iman J ^b   Gommans, Willemijn M ^b   Verheul, Mark ^b   Cerisoli, Francesco ^b   van Noort, Paula I ^b   Prevost, Gregoire P ^b   Schaapveld, Roel Q J ^b   Cuppen, Edwin ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b InteRNA Technologies BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 16; MICRORNA 182; MICRORNA 200A; MIR 15; MIR 203; MIR 497; MIR 96; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE LIBRARY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; PROTEIN FAMILY; RNA ANALYSIS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENOMICS; HUMANS; MELANOMA; MICE; MICRORNAS;

EID: 84865199648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043569     Document Type: Article

References (47)

1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA, ((2009)) Increasing burden of melanoma in the United States. J Invest Dermatol 129:: 1666--1674.
2. Jemal A, Siegel R, Xu J, Ward E, ((2010)) Cancer statistics, 2010. CA Cancer J Clin 60:: 277--300.
3. Rigel DS, Carucci JA (2000) Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 50: 215-236; quiz 237-240.
4. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, et al. ((2002)) Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:: 3728--3733.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. ((2002)) Mutations of the BRAF gene in human cancer. Nature 417:: 949--954.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. ((2010)) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:: 809--819.
7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. ((2010)) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:: 973--977.
8. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. ((2010)) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:: 968--972.
9. Bartel DP, ((2004)) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:: 281--297.
10. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, et al. ((2010)) MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328:: 1570--1573.
11. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, et al. ((2011)) MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma. Cancer Res 71:: 5214--5224.
12. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. ((2008)) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105:: 13027--13032.
13. Glud M, Manfe V, Biskup E, Holst L, Dirksen AM, et al. ((2011)) MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res 21:: 253--256.
14. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, et al. ((2010)) Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 40:: 841--849.
15. Mueller DW, Bosserhoff AK, ((2011)) MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer 129:: 1064--1074.
16. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, et al. ((2009)) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 106:: 1814--1819.
17. Poell JB, van Haastert RJ, Cerisoli F, Bolijn AS, Timmer LM, et al. ((2011)) Functional microRNA screening using a comprehensive lentiviral human microRNA expression library. BMC Genomics 12:: 546.
18. Cory AH, Owen TC, Barltrop JA, Cory JG, ((1991)) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:: 207--212.
19. Brideau C, Gunter B, Pikounis B, Liaw A, ((2003)) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8:: 634--647.
20. Yi R, Poy MN, Stoffel M, Fuchs E, ((2008)) A skin microRNA promotes differentiation by repressing 'stemness'. Nature 452:: 225--229.
21. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, et al. ((2008)) BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6:: 751--759.
22. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, et al. ((2006)) Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 66:: 8200--8209.
23. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, et al. ((1994)) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:: 527--532.
24. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. ((2005)) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:: 769--773.
25. McKenzie JA, Grossman D, ((2012)) Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 32:: 397--404.
26. Noguchi S, Mori T, Otsuka Y, Yamada N, Yasui Y, et al. ((2012)) Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 Protein in Human Melanoma Cells. J Biol Chem 287:: 11769--11777.
27. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D, ((2007)) MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem 282:: 25053--25066.
28. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. ((2005)) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:: 117--122.
29. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, et al. ((2005)) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37:: 1047--1054.
30. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, et al. ((2011)) Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30:: 1481--1488.
31. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, et al. ((2011)) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30:: 2307--2318.
32. Gray-Schopfer V, Wellbrock C, Marais R, ((2007)) Melanoma biology and new targeted therapy. Nature 445:: 851--857.
33. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, et al. ((2008)) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:: 650--656.
34. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. ((2010)) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:: 583--594.
35. Aqeilan RI, Calin GA, Croce CM, ((2010)) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17:: 215--220.
36. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. ((2002)) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:: 15524--15529.
37. Liu Q, Fu H, Sun F, Zhang H, Tie Y, et al. ((2008)) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36:: 5391--5404.
38. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, et al. ((2009)) miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69:: 5553--5559.
39. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. ((2005)) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102:: 13944--13949.
40. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al. ((2002)) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109:: 707--718.
41. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, et al. ((2004)) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:: 7002--7010.
42. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, et al. ((2011)) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:: 2750--2760.
43. Broderick JA, Salomon WE, Ryder SP, Aronin N, Zamore PD (2011) Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA.
44. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. ((2008)) Widespread changes in protein synthesis induced by microRNAs. Nature 455:: 58--63.
45. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. ((2005)) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:: e179.
46. Gommans WM, Berezikov E, ((2012)) Sample preparation for small RNA massive parallel sequencing. Methods Mol Biol 786:: 167--178.
47. Berezikov E, Thuemmler F, van Laake LW, Kondova I, Bontrop R, et al. ((2006)) Diversity of microRNAs in human and chimpanzee brain. Nat Genet 38:: 1375--1377.